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Abstract. Methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oate (CDDO-Me) has shown potent antitumorigenic 
activity against a wide range of cancer cell lines in vitro and 
inhibited the growth of liver, lung and prostate cancer in vivo. 
In the present study, we examined the antitumor activity of 
CDDO-Me for pancreatic ductal adenocarcinoma (PDAC) 
cells with and without activating K-ras mutations. Treatment 
of K-ras mutant MiaPaCa-2 and K-ras normal BxPC-3 cells 
with CDDO-Me elicited strong antiproliferative and proapop-
topic responses in both cell lines in culture. The inhibition of 
cell proliferation and induction of apoptosis was accompanied 
by the inhibition of antiapoptotic/prosurvival p-Akt, NF-кB 
and p-mTOR signaling proteins. For testing efficacy of 
CDDO-Me in vivo heterotopic and orthotopic xenografts were 
generated by implanting BxPC-3 and MiaPaCa-2 cells subcu-
taneously and in the pancreatic tail, respectively. Treatment 
with CDDO-Me significantly inhibited the growth of BxPC-3 
xenografts and reduced the levels of p-Akt and p-mTOR in 
tumor tissue. In mice with orthotopic MiaPaCa-2 xenografts, 
treatment with CDDO-Me prolonged the survival of mice 
when administered following the surgical resection of tumors. 
The latter was attributed to the eradication of residual PDAC 
remaining after resection of tumors. These preclinical data 
demonstrate the potential of CDDO-Me for treating primary 
PDAC tumors and for preventing relapse/recurrence through 
the destruction of residual disease.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% 
of all exocrine pancreatic cancers and is almost uniformly 
lethal with an estimated annual number of 45,220 new cases 
~38,460 annual deaths and a 5-year survival rate of <5% (1-3). 
Late initial diagnosis, aggressive metastatic behavior and resis-
tance to chemo-radiotherapy render pancreatic cancer one of 
the most difficult to treat of all malignancies. Systemic chemo-
therapy with either gemcitabine or FOLFIRINOX (5-FU, 
irinotecan and oxaliplatin) is the current standard of care for 
advanced PDAC, providing short-term symptomatic improve-
ment with minor impact on survival (4-6). Surgical resection 
is potentially curative; however, nearly 80% of the patients are 
diagnosed with locally advanced disease, precluding surgical 
intervention. Even in early stage PDAC patients in whom 
cancerous tissue is surgically resected (Whipple procedure), a 
majority of them relapse within two years after surgery. Thus, 
there is a tremendous need for novel therapeutics and treat-
ment strategies for treating primary and residual PDAC for 
preventing relapse after pancreatic cancer surgery.
Aberration of apoptosis has been implicated in carcino-
genesis and resistance to conventional anticancer therapies 
(7). Thus, promotion of apoptosis in cancer cells with novel 
agents could lead to tumor regression and improved prognosis. 
Triterpenes or triterpenoids are members of a large family of 
structurally related compounds known as cyclosqualenoids 
that are widely distributed in nature (8). Oleanolic acid is natu-
rally occurring triterpenoid that has been used in traditional 
medicine as an anticancer and anti-inflammatory agent (9-11). 
In order to increase the anti-inflammatory and anticancer 
activity of oleanolic acid several synthetic analogues have 
been synthesized. Synthetic lealane triterpenoid 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its C-28 
methyl ester derivative methyl-2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oate (CDDO-Me) and C-28 imidazole 
derivative 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imid-
azole (CDDO-Im) exhibit stronger anti-inflammatory activity 
than oleanolic acid (12,13). CDDOs have also shown potent 
antiproliferative and proapoptotic activity in diverse types of 
tumor cell lines through the inhibition of MAPK (Erk1/2), 
NF-κB and PPARγ signaling pathways and they induce cyto-
protective phase 2 response through Nrf2 signaling (14-20). In 
previous studies, we have demonstrated that the antiprolifera-
tive and apoptosis inducing activity of CDDO-Me in prostate 
cancer cell lines is mediated through the inhibition of anti-
apoptotic (prosurvival) Akt/NF-κB/mTOR signaling pathways 
(21). Although the antiproliferative activity of CDDOs in 
PDAC cell lines in vitro has been reported their therapeutic 
efficacy for PDAC in vivo has not been adequately studied. 
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we have investigated the therapeutic efficacy of CDDO-Me 
against heterotopic and orthotopic tumor xenografts generated 
with human PDAC cell lines with a focus on preventing or 
delaying relapse/recurrence. Our data show therapeutic effi-
cacy of CDDO-Me in treating primary tumor growth as well 
as in preventing/delaying recurrence of PDAC when adminis-
tered after surgical removal of tumors.
Materials and methods
Reagents. CDDO-Me was obtained from the National Cancer 
Institute, Bethesda, MD, uSA through the Rapid Access to 
Intervention Development Program. Antibodies against p-Akt 
(ser473), p-mtOR (Ser2448), PARP-1 and β-actin were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, uSA). 
Celltiter 96 AQueous One Solution Proliferation assay system 
was from Promega (Madison, wI, uSA) and Annexin V-FItC 
apoptosis detection kit II was obtained from BD Pharmingen 
(San Diego, CA, uSA).
Cell culture. human PDAC cell lines MiaPaCa-2 and BxPC-3 
were obtained from the American Type Culture Collection 
(AtCC, Rockville, MD, uSA). Cell lines were cultured at 
37˚C in a humidified atmosphere consisting of 5% CO2 and 
95% air and maintained by subculturing cells twice a week.
Mice. Six-week-old female Scid/Ncr mice were purchased 
from the Charles River Laboratories, Inc., Frederic, MD, 
uSA. Mice were maintained in a temperature-controlled room 
(68-72˚F) with a 12-h light/dark cycle and provided semi-puri-
fied AIN-76A mouse chow and water ad libitum. Mice were 
acclimated for one week before starting the experiment. All 
animal treatments were according to the protocol approved by 
the Institutional Animal Care and Use Committee (IACUC).
Measurement of cell viability. Tumor cells (1x104) were 
seeded into each well of a 96-well plate in 100 µl of tissue 
culture medium. After incubation at 37˚C in a humidified 
atmosphere consisting of 5% CO2 and 95% air for 24 h, cells 
were treated with CDDO-Me at concentrations of 0.625-5 µM 
for 72 h. Cell viability was then determined by the MtS assay 
using CellTiter 96® AQueous One Solution Proliferation assay 
system.
Measurement of apoptosis. Apoptosis was assessed by the 
binding of Annexin V-FItC to phosphotidylserine, which 
is externalized to the outer leaflet of the plasma membrane 
early during induction of apoptosis. Briefly, untreated cells 
and cells treated with CDDO-Me for 24 h were resuspended 
in the binding buffer provided in the Annexin V-FItC apop-
tosis detection kit and reacted with 5 µl of Annexin V-FItC 
reagent and 5 µl of propidium iodide (PI) for 30 min at 
room temperature in the dark. Stained cells were analyzed 
by flow cytometry using Accuri C6 flow cytometer (Accuri 
Cytometers Inc. Ann Arbor, MI, uSA). the induction of 
apoptosis by CDDO-Me was confirmed by the cleavage of 
PARP-1 by western blotting.
Western blotting. Cell lysates were prepared using NP 40 
cell lysis buffer. Lysates were clarified by centrifugation at 
14,000 x g for 10 min at 4˚C and protein concentrations were 
determined. Samples (50 µg) were boiled in an equal volume 
of sample buffer [20% glycerol, 4% SDS, 0.2% bromophenol 
blue, 125 mM Tris-hCl (ph 7.5), and 640 mM 2-ME] and 
separated on pre-casted Tris-glycine polyacrylamide gels 
using the XCell Surelock™ Mini-Cell, in tris-glycine SDS 
running buffer, all from Novex (Invitrogen, Carlsbad, CA, 
uSA). Proteins resolved on the gels were transferred to PVDF 
membranes. Membranes were blocked with 5% milk in 10 mM 
Tris-hCl (ph 8.0), 150 mM NaCl with 0.05% Tween-20 
(tPBS) and probed using specific antibodies against proteins 
of interest or β-actin (loading control) and hRP-conjugated 
secondary antibody. Immune complexes were visualized with 
enhanced chemiluminescence. Protein bands were imaged and 
band densities analyzed using the NIh/Scion image analysis 
software. The protein band densities were normalized to the 
corresponding β-actin band densities and percent change in 
signal strength was calculated.
Generation of tumor xenografts. heterotopic PDAC xeno-
grafts were generated by implanting 1x106 BxPC-3 cells in 
50 µl of PBS subcutaneously in the right flank of 7-week-old 
Scid-Ncr female mice. Cells were allowed to form tumors for 
7 days before initiating treatment with CDDO-Me. Orthotopic 
PDAC xenografts were generated by implanting MiaPaCa-2 
cells stably expressing luciferase gene (MiaPaCa-2-Luc cells) 
in the pancreatic tail of Scid/Ncr mice. Briefly, mice were 
anesthetized with ketamine/xylazine (100/8 mg/kg i.p.) and 
a 2-cm long subcostal laparotomy was performed after clip-
ping hair. Pancreas were exposed and 1x106 MiaPaCa-2-Luc 
cells in 20 µl of PBS were injected in the pancreatic tail with a 
30 G needle. Proper deposition of cells was confirmed by bleb 
formation at the site of injection. The fascia and skin incisions 
were sutured following implantation of tumor cells.
Residual disease. To generate residual disease, 1x106 MiaPaCa-
2-Luc cells in 20 µl of PBS were injected in the pancreatic tail 
as described above. Cells were first allowed to form tumors 
for 28 days and then mice were anesthetized with ketamine/
xylazine (100/8 mg/kg i.p.) and partial pancreatectomy was 
performed to remove all visible tumor growth. After resection 
of tumors, incisions were sutured and mice were either treated 
or not with CDDO-Me.
Treatment with CDDO-Me. Two treatment paradigms were 
followed. To treat primary tumor growth, treatment was started 
on day 7 after implantation of BxPC-3 cells subcutaneously. 
To treat residual disease, treatment was started one day after 
resection of tumors on day 28 after implantation of MiaPaCa-
2-Luc cells in the pancreas. Mice in both treatment paradigms 
were administered CDDO-Me at a dose of 15 µmol/kg 
(7.5 mg/kg), 5 days a week in 0.1 ml of vehicle consisting of 
cremophor-eL:DMSO:PBS (1:1:8) by oral gavage until day 40 
(heterotopic xenografts) to treat primary tumor growth or day 
100 (orthotopic xenografts) to treat residual disease. Control 
mice were treated with vehicle alone without CDDO-Me.
Bioluminecsent imaging (BLI). The growth progression 
of orthotopic PDAC xenografts generated by implanting 
MiaPaCa-2-Luc cells in the pancreas was measured 
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non-invasively by BLI imaging using Kodak Multispectral 
Imaging system (Carestream health, woodbridge, Ct, uSA). 
Briefly, mice were anesthetized with isofluorane and anesthesia 
was maintained by inhalation of a mixture of isofluorane (2%) 
and oxygen during the imaging procedure. First an X-ray 
image was taken and then BLI was obtained for 2 min, 10 min 
after i.p. injection of sodium luciferin (150 mg/kg). The X-ray 
and BLI images were overlaid and peak photon flux (photon/
sec/mm2) from the tumors was plotted against time to obtain 
tumor growth curve.
Statistical analysis. Most data are presented as means ± SD 
and outcomes for treated and untreated cells were compared 
by Student's t-test. Differences were considered significant at 
p<0.05.
Results
CDDO-Me inhibits proliferation and induces apoptosis in 
PDAC cells. To test the effect of CDDO-Me on the prolifera-
tion of PDAC cells, 1x104 MiaPaCa-2 or BxPC-3 cells were 
plated in 96-well microtiter plates for 24 h and then treated with 
CDDO-Me for 72 h at concentrations ranging from 0 to 5 µM. 
Viability of cultures was assessed by MtS assay and percent 
reduction in viability of cultures was determined. As shown in 
Fig. 1, significant decrease in the viability of cell cultures was 
observed in both cell lines treated with CDDO-Me at concen-
trations of 1.25-5 µM (MiaPaCa-2: 44-73%; BxPC-3: 57-79%).
To determine whether inhibition of proliferation of 
PDAC cells by CDDO-Me was associated with induction of 
apoptosis, binding of Annexin V-FItC to cells treated with 
CDDO-Me was measured. For this, MiaPaCa-2 or BxPC-3 
cells were treated or not with CDDO-Me (0-5 µM) for 24 h 
and analyzed for Annexin V-FItC binding by flow cytometry. 
As shown in Fig. 2A, the percentage of Annexin V-FItC 
binding MiaPaCa-2 cells increased from <2% (untreated cells) 
to 17, 24, 37 and 62% following treatment with CDDO-Me 
at 0.625, 1.25, 2.5 and 5 µM, respectively. The percentage of 
Annexin V-FItC binding BxPC-3 cells was 1, 9, 16, 56 and 
67% at 0, 0.625, 1.25, 2.5 and 5 µM CDDO-Me.
Figure 1. CDDO-Me inhibits the proliferation of PDAC cells. MiaPaCa-2 or BxPC-3 cells (1x104) in 100 µl of culture medium were seeded in each well of a 
96-well microtiter plate and allowed to adhere for 24 h. Cells were treated with CDDO-Me at concentrations ranging from 0 to 5 µM for 72 h in triplicate. Cell 
viability was measured by MtS assay using Celltiter AQueous assay system from Promega. Data are presented as percent reduction in viability obtained in 
three independent experiments. *p≤0.05 compared to control cells (no CDDO-Me).
Figure 2. CDDO-Me induces apoptosis in PDAC cells. (A) Binding of 
Annexin V-FItC. MiaPaCa-2 cells and BxPC-3 cells were treated with 
CDDO-Me at concentrations of 0-5 µM for 24 h. Cells were then reacted 
with 5 µl of Annexin V-FItC and 5 µl PI for 30 min at room temperature 
in the dark. the percentage of Annexin V-FItC-positive tumor cells was 
determined by flow cytometry. (B) Cleavage of PARP-1. MiaPaCa-2 cells and 
BxPC-3 cells were treated with CDDO-Me (0-5 µM) for 24 h. Cell lysates 
were analyzed for cleavage of PARP-1 by western blotting. Experiment was 
repeated twice.
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the induction of apoptosis by CDDO-Me was confirmed 
by the cleavage of native PARP-1. As shown in Fig. 2B, treat-
ment with CDDO-Me caused the emergence of 89 kDa cleaved 
PARP-1 fragment in both cell lines. Together, increase in 
binding of Annexin V-FItC and cleavage of PARP-1 demon-
strated induction of apoptosis by CDDO-Me in PDAC cells.
CDDO-Me inhibits p-Akt, NF-кB and p-mTOR signaling 
proteins in PDAC cells. Akt, NF-кB and mtOR are 
anti-apoptotic (prosurvival) signaling proteins that are 
constitutively active in a variety of human cancers, providing 
survival advantage to cancer cells. We investigated whether 
PDAC cells express constitutively active Akt (p-Akt) and 
mTOR (p-mTOR) and the effect CDDO-Me has on the 
expression of these signaling proteins. Cell lysates were 
prepared from MiaPaCa-2 and BxPC-3 cells treated or not 
with CDDO-Me (0-5 µM) for 24 h and analyzed by western 
blotting for the levels of these proteins. Fig. 3 shows that both 
PDAC cell lines expressed p-Akt, NF-кB and p-mtOR and 
treatment with CDDO-Me significantly or completely inhib-
ited their expression at concentrations of 1.25-5 µM. These 
data demonstrated that induction of apoptosis by CDDO-Me 
is attributable at least in part to the inhibition of anti-apoptotic 
Akt, NF-κB and mTOR.
CDDO-Me inhibits the growth of BxPC-3 xenografts. Next we 
determined the tumor inhibitory activity of CDDO-Me in vivo 
against hetrotopic BxPC-3 xenografts. One week after injec-
tion of 1x106 BxPC-3 PDAC cells in the flanks of Scid-Ncr 
mice, mice were treated with CDDO-Me (15 µmol/kg) or 
vehicle only by oral gavage, 5 days/week for 5 weeks (n=5) and 
experiment was terminated on day 40. To measure the effect 
of CDDO-Me on progression of tumor growth, tumor dimen-
tions (length and width) were measured by a caliper and tumor 
volume was calculated by the formula: (length x width2)/2. 
As shown in Fig. 4A, treatment with CDDO-Me significantly 
inhibited the growth of BxPC-3 xenografts compared to 
vehicle contol animals [tumor volume (mm3 ± SD): control, 
53±10, 98±23, 226±21 and 284±39; CDDO-Me, 22±6, 37±10, 
79±16 and 111±19 on days 14, 21, 28 and 35 after implantation 
of tumor cells]. Furthermore, treatment with CDDO-Me also 
reduced p-Akt and p-mTOR levels in the tumor tissue (76 and 
54% reduction, respectively) (Fig. 4B). These data demon-
strated therapeutic efficacy of CDDO-Me against PDAC 
in vivo and provided evidence that activated Akt and mTOR 
are therapeutic targets of CDDO-Me in PDAC tumors.
Generation of orthotopic PDAC xenografts and efficacy of 
CDDO-Me for residual disease. To closely mimic physiolog-
ical microenvironment of PDAC in patients for treatment with 
CDDO-Me we generated orthotopic xenografts by injecting 
MiaPaCa-2-Luc cells in the pancreatic tail in Scid/Ncr mice. 
The development and progression of orthotopic xenografts 
Figure 3. CDDO-Me downregulates prosurvival signaling proteins in PDAC cells. MiaPaCa-2 and BxPC-3 cells were treated with CDDO-Me (0-5.0 µM) for 
24 h. Levels of p-Akt, NF-κB (p65), p-mTOR, and β-actin (loading control) were analyzed by western blotting. Experiment was repeated two times.
Figure 4. CDDO-Me inhibits growth of PDAC xenografts and expression of 
prosurvival signaling proteins in tumor tissue. (A) BxPC-3 cells (1x106) in 
50 µl of PBS were injected in the flank of seven-week-old female Scid/Ncr 
mice. Starting on day 7 after implantation of tumor cells mice were treated 
with CDDO-Me at a dose of 15 µmol/kg by oral gavage as described in 
Materials and methods. Control mice were treated with vehicle alone without 
CDDO-Me. Tumor dimensions (length and width) were measured with a 
caliper at weekly intervals. Data are plotted as tumor volumes vs days past 
tumor cell implantation ± SD. (B) At termination of the experiment (day 40), 
tumor tissue from control and CDDO-Me treated mice was harvested and 
levels of p-Akt and p-mTOR were analyzed by western blotting.
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was monitored non-invasively by bioluminescence imaging 
using Kodak Multispectral Imaging System (Carestream 
health, woodbridge, Ct, uSA). Fig. 5 shows BLI images of a 
xenograft on days 15 and 35 (Fig. 5A and B) and a metastatic 
lesion in the liver (Fig. 5B, arrow). The growth curve of xeno-
grafts was created by plotting photon flux emission (photons/
sec/mm2) from tumors at various time points past tumor cell 
injection in the pancreas (Fig. 5C). The anatomical location of 
tumors was visually confirmed upon opening the abdominal 
cavity and tumors were harvested and identified as PDAC 
histologically (Fig. 5D and E).
We used the orthotopic xenogaft model to generate residual 
disease to investigate efficacy of CDDO-Me for preventing 
relapse (recurrence) after surgical removal of tumors. In this 
case, after injection of MiaPaCa-2-luc cells in the pancreatic 
tail, tumor cells were first allowed to form tumors. On day 28, 
tumors were resected to remove all of the visible tumor growth 
in each animal. One day after removal of tumors, mice were 
treated with vehicle alone (n=9) or CDDO-Me by oral gavage 
at a dose of 15 µmol/kg as described in Materials and methods 
(n=12). Separately, mice were also treated with gemcitabine, 
the standard drug used for treating pancreatic cancer, at a 
dose of 2 mg/kg, 2 times per week, i.p. (n=9). Experiment was 
terminated on day 100 and survival data were compared. 
As shown in Fig. 5F, six of the nine mice in the vehicle 
control group died during this period (33% survival; mean 
survival time =81.6±22 days). Five of the nine mice treated 
with gemcitabine survived during the same period (56% 
survival; mean survival time =81±25 days, p>0.05). however, 
the group of mice treated with CDDO-Me showed the best 
survival rate, i.e., eight of the 12 mice treated with CDDO-Me 
revealed the presence of tumours in 2 of the 3 vehicle control, 2 
of the 5 gemcitabine-treated and 1 of the 8 CDDO-Me-treated 
surviving mice on day 100.
Discussion
Pancreatic ductal adenocarcinoma is an intractable malig-
nant disease with limited therapeutic options. Discovering 
effective novel agents with defined therapeutic targets might 
provide urgently needed therapeutics to treat this cancer. 
Natural products have long been recognized as a rich source 
of chemical diversity and compounds with a wide spectrum 
of anticancer activities. From vincristine to paclitaxel, the 
effective antitumor activity and novel mechanisms of action 
of many natural compounds and their synthetic derivatives 
have been described (22,23). CDDO and CDDO-Me are 
synthetic triterpenoids derived from oleanolic acid with 
Figure 5. Bioluminescent imaging of orthotopic PDAC xenografts and efficacy of CDDO-Me in preventing recurrence. Female Scid/Ncr mice were injected 
with 1x106 MiaPaCa-2 cells stably expressing luciferase gene (MiaPaCa-2-Luc cells) in the pancreatic tail. The growth of xenografts was monitored by 
non-invasive bioluminescent imaging (A and B) and a growth curve was generated by plotting BLI signals from tumors (photon emission/sec/mm2) vs time 
(days) after implantation of MiaPaCa-2-Luc cells (C). Size and histology of a tumor harvested on day 35 is also shown (D and e). (F) to determine efficacy 
of CDDO-Me for preventing relapse, all visible tumor growth was resected on day 28 after implantation of MiaPaCa-2-Luc cells and mice were treated with 
CDDO-Me at a dose of 15 µmol/kg orally, 5 days a week until day 100. Control mice were treated with vehicle alone without CDDO-Me. In a separate group, 
mice were also treated with gemcitabine i.p., twice a week at a dose of 2 mg/kg to compare the activity of CDDO-Me to that of a standard agent for PDAC. 
Kaplan-Meier plots (F) represent survival data of vehicle only, gemcitabine or CDDO-Me treated animals. 
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potent antiproliferative and pro-apoptotic activity. Earlier 
we demonstrated efficacy of CDDO and CDDO-Me in 
preventing/delaying the development and progression of pros-
tate cancer in the transgenic TRAMP mouse model of prostate 
tumorigenesis (24,25). Others have shown efficacy of CDDOs 
for breast, lung and colon cancers (26,27). On the other hand, 
therapeutic efficacy of CDDOs for pancreatic cancer has not 
been adequately investigated. Studies described in this report 
were intended to determine therapeutic efficacy of CDDO-Me 
for pancreatic ductal adenocarcinoma. Since Kras is mutated 
in >90% of human PDAC and mutation of Kras at codon 
G12 leads to constitutive activation of Kras oncoprotein and 
more aggressive PDAC phenotype (28), we investigated the 
anticancer activity of CDDO-Me in vitro and in vivo using 
two PDAC cell lines with and without activating K-ras muta-
tions (MiaPaCa-2 and BxPC-3, respectively). CDDO-Me 
strongly inhibited the proliferation of both cell lines in vitro 
independent of K-ras mutations. Since inhibition of cell 
proliferation induces apoptosis in cancer cells, we assessed 
induction of apoptosis by CDDO-Me in PDAC cells. Induction 
of apoptosis was measured by the binding of Annexin V-FItC 
to phosphotidylserine which is externalized to the outer 
leaflet of the plasma membrane early during induction of 
apoptosis. treatment with CDDO-Me significantly increased 
the percentage of Annexin V-FItC binding cells in both cell 
lines. Induction of apoptosis was confirmed by the cleavage of 
PARP-1, a hallmark of cells undergoing apoptosis.
PI3K/Akt/mtOR and Akt/NF-кB are major antiapoptotic/
prosurvival signaling pathways that are constitutively active in 
most cancers including pancreatic cancer. Akt promotes cell 
growth and survival by inactivating downstream substrates 
such as Bad, procaspase-9 and forkhead transcription factors 
(28,29). Antiapoptotic NF-κB and progrowth mTOR signaling 
pathways are downstream targets of activated PI3K/AKT. The 
NF-κB family of transcription factors controls the expression 
of genes involved in immune, inflammatory and oncogenic 
responses and play a critical role in resistance of cancer cells 
to anticancer therapies by protecting them from apoptosis 
(30). mTOR is a serine-threonine kinase, which controls cell 
growth, survival and ribogenesis (31). CDDO-Me inhibited 
the expression of p-AKT, NF-κB and p-mTOR in MiaPaCa-2 
and BxPC-3 cells. The inhibition of these anti-apoptotic and 
survival-promoting signaling proteins suggested that they are 
involved in mediating the antiproliferative and proapoptotic 
activity of CDDO-Me in PDAC cells.
The results of in vitro studies showing strong antiprolif-
erative and proapoptotic activity of CDDO-Me for PDAC 
cells prompted us to evaluate its therapeutic efficacy for 
PDAC in vivo, since many times antitumor effects observed 
in cell lines in vitro do not pan out in vivo. we first exam-
ined CDDO-Me for therapeutic efficacy against heterotopic 
xenografts generated with BxPC-3 cells with normal K-ras 
expression. treatment with CDDO-Me significantly inhibited 
the growth of heterotopic xenografts (p<0.01). Western blot 
analysis of the tumor tissue extract showed that the inhibition 
of tumor growth was associated with the inhibition of anti-
apoptotic/prosurvival p-Akt, NF-кB and p-mtOR signaling 
proteins. These data also demonstrated that in vitro effects 
of CDDO-Me in PDAC cells does translate into therapeutic 
efficacy in vivo.
to further analyze therapeutic efficacy of CDDO-Me for 
PDAC, we tested it for preventing relapse/recurrence when 
administered after surgical resection of tumors. This was 
accomplished by creating a model of PDAC residual disease 
wherein orthotopic PDAC xenografts generated by implanting 
MiaPaCa-2-Luc cells in the pancreas were surgically removed 
after four weeks of tumor growth. Treatment with CDDO-Me 
in this adjuvant setting significantly prolonged survival of mice 
compared to untreated animals. In fact, the survival advantage 
with CDDO-Me was even better than that with gemcitabine, 
a standard drug for the treatment of patients with advanced 
PDAC. Thus, therapeutic outcomes in xenografts models 
generated with PDAC cells expressing either normal K-ras 
(BxPC-3) or activated K-ras (MiaPaCa-2) correlated with 
responses to CDDO-Me in vitro. Although the exact mecha-
nism of the antitumor activity of CDDO-Me in vivo remain to 
be investigated, our data suggest that downregulation of p-Akt, 
NF-кB and p-mtOR signaling proteins plays a role in inhibi-
tion of cell proliferation and induction of cellular apoptosis in 
tumor cells by CDDO-Me. Since treatment with gemcitabine 
or CDDO-Me alone improved survival when administered 
after removal of tumors suggests that combinatorial regimen 
of gemcitabine and CDDO-Me might be even more beneficial 
in preventing/delaying recurrence. This inference of course 
needs more rigorous analysis in these preclinical models of 
PDAC.
In conclusion, our investigations show that CDDO-Me 
exhibits therapeutic efficacy in xenograft models of PDAC 
(heterotopic and orthotopic) for inhibiting primary tumor 
growth and delaying/preventing relapse by destroying residual 
disease. Because of its ability to inhibit p-AKT, NF-κB and 
p-mTOR in tumor tissue, we speculate that CDDO-Me inhibits 
tumor growth by inhibiting cell proliferation and promoting 
apoptosis through the inhibition of anti-apoptotic/prosurvival 
AKT/NF-κB/mTOR signaling pathways. Collectively, these 
findings unveiling antitumor potential of CDDO-Me for PDAC 
warrant further studies for development of CDDO-Me as an 
adjuvant to existing PDAC therapies to obtain more durable 
responses and improved outcomes.
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